about
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibEndothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptorThe PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsMucorales-Specific T Cells in Patients with Hematologic Malignancies.Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis.Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF.Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone.Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status.Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement.Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance.Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological FeaturesIGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemiaMolecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre studyStereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter SyndromeChromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosisComprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter studyAngiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational statusNOX-A12: mobilizing CLL away from homeVorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell linesIdentification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primersAcute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer AnswersOverexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS
P50
Q27025812-D9B0970C-0039-4DE5-BDD8-BC0CBA6CCA6CQ28539394-13837E36-080D-45DC-B39C-E435EEBCD915Q35078248-39C0F59D-653A-489D-9EF2-F96B80836B15Q35922089-5012FC24-EB4D-41D3-8206-5DC87E0BE0ECQ36006453-EF083B75-3C54-4E70-8A9F-4D7D76FBDA5BQ36715966-B3191C92-4ED9-4144-A714-B33541D16518Q36967153-EF623C28-B663-4708-87C1-A3F7A0546055Q37192643-CE540B6C-6B1A-400C-B1AC-2146B04E9F49Q38030534-A8A9C44A-6DAF-4921-A21E-EEF5968F847AQ38603785-45C312E9-4E3B-4539-BD16-67569F7BBF38Q39962023-B8855981-A646-4F66-8926-4AF97903D50DQ44556743-763942A1-C3CB-49D0-A678-FDB35D528C91Q44930034-920BC914-0B8D-4E45-A919-BF28673BA283Q45922582-8647D472-32E0-42D4-8488-67FF11675CFBQ45988365-913D60AB-D3D7-46B8-9C8F-F57B5074765DQ46446491-A6137D88-8CBA-477E-9C4F-FE6CE27AF1FFQ46562795-83B87B8B-6425-46A3-876A-070D106DB562Q46755084-5D7ADDFB-DA99-4743-8C69-5B1A3E4D9EB9Q46790741-81653031-50AC-4B3C-A5E4-FD33E66A5B63Q48330774-F6A2D162-02B2-45BD-95CC-A49711DA5684Q50784041-D3DF90BD-B664-458A-B0F3-4AA53E71095BQ51686376-6F16AD16-F593-4484-8CA7-EF824CAD3B0FQ53330290-8D81299D-9490-40A4-AD8C-6539D3AB6A21Q53522638-DF0043C1-F6A2-4679-899F-1B44D6189F1AQ58000969-2F826AFA-25D3-4774-91C6-C0B32400E2D6Q58000974-0BE8F1DC-BA4F-4923-919C-1E8BA34BFB44Q58001001-696449E3-9913-4DC2-B71D-04E97CA66D9DQ58001002-2BCD6182-55DA-4F50-BA3C-A12884B6AF0FQ58001012-E9F50DB0-8D5F-4171-9C61-6D952D6ED6BEQ58001030-2173F88C-7B8C-4789-9628-EE0E98A2C736Q60584738-BB647B40-38DA-41D2-9E9B-5CD9D0A5BEB1Q61952016-EA8508E2-FC91-4D32-BA0E-B6513981A3AEQ61952100-ED737B79-1847-4638-BFF5-665336EB12B3Q61952126-69070718-4F91-4A5C-B252-9E8725F4FF45Q89633732-D27AB812-BDB3-45B0-AF3E-ADFCDF3B2AC4Q91117738-3555068C-D9E0-4EF6-9DD7-87E98291526F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rossana Maffei
@ast
Rossana Maffei
@en
Rossana Maffei
@es
Rossana Maffei
@nl
Rossana Maffei
@sl
type
label
Rossana Maffei
@ast
Rossana Maffei
@en
Rossana Maffei
@es
Rossana Maffei
@nl
Rossana Maffei
@sl
altLabel
Rossana Maffei
@en
prefLabel
Rossana Maffei
@ast
Rossana Maffei
@en
Rossana Maffei
@es
Rossana Maffei
@nl
Rossana Maffei
@sl
P1053
O-4836-2016
P106
P1153
23492785900
P21
P31
P3829
P496
0000-0002-3518-2006